Blue Sky Thinking: CEOs, Analysts Offer Some Thoughts On 2022
As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.
You may also be interested in...
Medtech Insight spoke to the CEOs Blackrock Neurotech, and Pixium Vision, to find out how their devices can restore lost neurological function, and how devices that interface with the brain may shape the future of medicine.
Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.
Despite intense lobbying from industry and physician groups, CMS chose not to install national pricing for long-term remote cardiac monitoring in its final 2022 Medicare Physician Fee Schedule Final Rule.